MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$9,947K
Free Cash flow
$3,861K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from exercise of stock ...
    • Share-based compensation
    • Net income (loss)
    • Others
Negative Cash Flow Breakdown
    • Proceeds from initial public off...
    • Accounts receivable
    • Deferred revenue
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net income (loss)
5,294
14,967
-3,178
-14,759
Depreciation and amortization
1,581
-2,536
1,359
2,685
Share-based compensation
5,631
-5,001
3,536
5,674
Loss on debt extinguishment
-
-
-2,109
-
Loss on disposal of property and equipment
-25
0
0
-2
Amortization of debt issuance costs
0
-285
33
252
Non-cash operating lease expense
0
-447
65
382
Change in fair value of warrant liabilities
0
-1,468
212
1,256
Provision for credit losses
383
-679
995
490
Amortization of deferred commissions
968
-1,509
906
1,561
Accounts receivable
16,971
-13,308
9,154
10,360
Inventory
288
-507
-321
173
Prepaid expenses and other current assets
-1,279
-31
700
870
Deferred commissions
655
-117
896
1,423
Other non-current assets
-11
242
-63
-118
Accounts payable
3,650
-3,497
357
1,016
Operating lease liabilities
0
415
0
-415
Accrued expenses and other current liabilities
4,751
-16,947
12,562
-4,780
Deferred revenue
-1,652
-3,332
1,632
5,995
Other non-current liabilities
0
0
-89
89
Net cash used in operating activities
4,007
-8,707
10,133
-13,260
Purchases of property and equipment
146
-1,045
537
586
Capitalized internal-use software costs
1,518
-1,884
1,450
1,913
Net cash used in investing activities
-1,664
2,929
-1,987
-2,499
Proceeds from exercise of stock options
8,137
-2,746
2,085
3,908
Taxes paid related to net share settlement of equity awards
533
127
-
-
Payment of deferred offering costs
0
-4,284
2,357
1,927
Repayment of debt principal
-
-
30,963
-
Payment of debt extinguishment costs
-
-
1,430
-
Proceeds from initial public offering, net of underwriting discounts and commissions
-160,532
-
0
160,532
Net cash provided by financing activities
7,604
-126,728
-32,665
162,513
Net increase (decrease) in cash and cash equivalents
9,947
-132,506
-24,519
146,754
Cash and cash equivalents at beginning of period
198,627
198,627
76,392
-
Cash and cash equivalents at end of period
221,712
211,765
198,627
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

something is missing$160,532K Share-based compensation$5,631K (-0.76%↓ Y/Y)Proceeds from exercise ofstock options$8,137K (108.21%↑ Y/Y)Net income (loss)$5,294K (135.87%↑ Y/Y)Accrued expenses andother current...$4,751K (199.39%↑ Y/Y)Accounts payable$3,650K (259.25%↑ Y/Y)Depreciation andamortization$1,581K (-41.12%↓ Y/Y)Prepaid expenses andother current assets-$1,279K (-247.01%↓ Y/Y)Amortization of deferredcommissions$968K (-37.99%↓ Y/Y)Provision for creditlosses$383K (-21.84%↓ Y/Y)Loss on disposal ofproperty and equipment-$25K (-1150.00%↓ Y/Y)Other non-currentassets-$11K (90.68%↑ Y/Y)Net cash provided byfinancing activities$7,604K (-95.32%↓ Y/Y)Net cash used inoperating activities$4,007K (130.22%↑ Y/Y)Canceled cashflow$161,065K Canceled cashflow$19,566K Net increase(decrease) in cash and cash...$9,947K (-93.22%↓ Y/Y)Canceled cashflow$1,664K Proceeds from initialpublic offering, net of...-$160,532K (-200.00%↓ Y/Y)Taxes paid related tonet share...$533K Accounts receivable$16,971K (63.81%↑ Y/Y)Deferred revenue-$1,652K (-127.56%↓ Y/Y)Deferred commissions$655K (-53.97%↓ Y/Y)Inventory$288K (66.47%↑ Y/Y)Net cash used ininvesting activities-$1,664K (33.41%↑ Y/Y)Capitalized internal-usesoftware costs$1,518K (-20.65%↓ Y/Y)Purchases of property andequipment$146K (-75.09%↓ Y/Y)

Omada Health, Inc. (OMDA)

Omada Health, Inc. (OMDA)